Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 14:01 save search
Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Published: 2021-03-01 (Crawled : 14:01) - globenewswire.com
VERU | $1.27 -3.05% -3.15% 1.3M
|
Health Technology
|
| O: 12.3%
H: 0.84%
C: -7.15%
covid fda risk respiratory phase 3 syndros
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Published: 2021-02-24 (Crawled : 14:01) - globenewswire.com
LGVN 4 d | $1.87 -2.6% 0.0% 8K
|
|
| O: 0.47%
H: 20.74%
C: 18.42%
heart phase 1 injection phase 3 phase 2 syndros lomecel-b
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
Published: 2021-02-22 (Crawled : 14:01) - globenewswire.com
SAVA M | $20.5 4.38% 4.38% 4.2K
|
Health Technology
|
| O: 17.89%
H: 0.0%
C: -19.34%
disease alzheimer fda phase 2 positive phase 3 alzheimer’s alzheimer's disease alzheimer's
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Published: 2021-02-03 (Crawled : 14:01) - globenewswire.com
VXRT | News | $0.7625 0.91% 0.9% 940K
|
Health Technology
|
| O: -53.56%
H: 17.58%
C: -9.09%
covid positive vaccine trial phase 3 phase 1 phase 2
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
PHAT | $9.01 0.45% 0.55% 0
|
Health Technology
|
| O: 1.6%
H: 1.49%
C: 1.02%
phase 3 trial enroll
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Published: 2021-01-13 (Crawled : 14:01) - globenewswire.com
ARQT | $8.94 -1.76% -1.9% 2.2K
|
Health Technology
|
| O: -0.92%
H: 4.67%
C: 0.26%
dermatitis phase 3 trial treatment potential atopic dermatitis
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Published: 2021-01-12 (Crawled : 14:01) - globenewswire.com
RZLT 4 | $3.54 3.21% 2.28% 11K
|
Technology Services
|
| O: 2.3%
H: 4.73%
C: 4.45%
diabetic macular phase 3 phase 1 phase 2 treatment diabetes
Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -10.58%
H: 2.98%
C: 2.97%
insulin phase 3 trial pharma
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 3.14%
H: 1.5%
C: -2.26%
phase 3 treatment enroll
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT | $8.94 -1.76% -1.9% 2.2K
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
SMFL | $4.35 29.2% 47.55% 4.2M
|
Manufacturing
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PROK | $2.72 33.33% 26.88% 20K
|
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SGD | $0.685 -1.71% 22.48% 2M
|
n/a
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.